An Open-Label Clinical Study to Evaluate the Safety and Gastrointestinal Tolerance (Product Compliance) of Groviva® Advance in Hospitalized Children Requiring Isocaloric Formula for Enteral Tube Feeding
The aim of this study is to evaluate the safety and gastrointestinal tolerance of Groviva® Advance in pediatric patients hospitalized to Pediatric Intensive Care Units (PICUs) and requiring an isocaloric formula for enteral tube feeding. This was a prospective five-day single centre, open label clinical study. The safety and tolerance of Groviva® Advance (45 gram in 170 millilitres of water) was evaluated every day from Day 1 to the end of hospitalization or Day 5, whichever was earlier. The reconstituted amount was 210 millilitres (equivalent to 200 kcal [1 kcal in 1 ml]) and dosed three hourly (or at the discretion of the pediatrician). The majority of participants received the Groviva® Advance tube feed three hourly on all five days of the study. The average range of total feeds varied from 295.16 ± 275.19 to 1074.737 ± 347.94 feeds per day. The most common side effects were loose stools or vomiting; if present, majority of participants had only one episode per day. There was minimal or no total daily aspiration or GRV (>500 ml/day). There was no statistically significant change in weight (P=0.7163) and abdominal girth (0.6381) of study participants. There were no issues encountered during the preparation and administration of Groviva® Advance. Groviva® Advance was found to be safe and well tolerated by critically ill children admitted to PICUs.